v3.26.1
Organization and Basis of Presentation - Summary of Company's Consolidated Statements of Operations (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenues [Abstract]            
Total revenues $ 33,741   $ 33,637   $ 64,634 $ 71,531
Cost of sales 7,855   8,447   15,250 18,013
Total costs and expenses 47,511   47,640   96,233 96,208
Loss from operations (13,770)   (14,003)   (31,599) (24,677)
Interest expense (3)   (5)   (6) (11)
Interest and other income 1,764   2,254   3,718 4,762
Loss before income taxes (12,009)   (11,754)   (27,887) (19,926)
Income tax expense 88   32   94 50
Net loss (12,097) $ (15,884) (11,786) $ (8,190) (27,981) (19,976)
Product sales            
Revenues [Abstract]            
Total revenues 27,241   33,637   58,134 71,531
License and collaboration revenue            
Revenues [Abstract]            
Total revenues 6,500   0   6,500 0
Commercial [Member]            
Revenues [Abstract]            
Total costs and expenses 19,872   21,612   40,083 42,786
General and Administrative [Member]            
Revenues [Abstract]            
Total costs and expenses 10,546   7,364   22,191 14,825
Research and Development [Member]            
Revenues [Abstract]            
Total costs and expenses 7,529   8,865   15,364 17,921
Clinical and Regulatory [Member]            
Revenues [Abstract]            
Total costs and expenses $ 1,709   $ 1,352   $ 3,345 $ 2,663